NEW YORK,
June 2,
2023 /PRNewswire/ -- Jakubowitz Law announces that an
investigation into potential securities fraud allegations has
commenced on behalf of shareholders of Phathom Pharmaceuticals,
Inc. (NASDAQ: PHAT)
To be contacted by a member of our team, fill
out the form:
https://claimyourloss.com/securities/phathom-class-action-loss-submission-form/?id=40183&from=4
Further details on the investigation: On
August 2, 2022, before market hours,
Phathom issued a press release entitled "Phathom Pharmaceuticals
Reports Second Quarter 2022 Financial Results and Provides Business
Updates" which announced that "we detected trace levels of a
nitrosamine in vonoprazan drug product in our post-approval testing
as we prepared for commercial launch." Further, the press release
announced that "[t]he Company is working with the FDA and plans to
obtain approval of and implement an additional test method,
specification, including a proposed acceptable intake limit, and
additional controls to address this impurity prior to releasing our
first vonoprazan-based products to the market." Finally, Phathom
announced that "[t]hese additional activities will result in a
delay of the planned VOQUEZNA DUAL PAK and VOQUEZNA TRIPLE PAK
product launches." On this news, Phathom's stock price fell
$2.61 per share, or 28%, to close at
$6.46 per share on August 2, 2022.
Jakubowitz Law is vigorous in pursuit of justice
for shareholders who have been the victim of securities fraud.
Attorney advertising. Prior results do not guarantee similar
outcomes.
CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (628) 895-0423
F: (212) 537-5887
View original
content:https://www.prnewswire.com/news-releases/phat-fraud-alert-jakubowitz-law-is-investigating-phathom-pharmaceuticals-inc-in-connection-with-potential-violations-of-federal-securities-laws-301840872.html
SOURCE Jakubowitz Law